Exit interviews from two randomised placebo-controlled phase 3 studies with caregivers of young children with autism spectrum disorder by Natalia Hawken, Bruno Falissard, Carl Choquet, Clement Francois, Jean Tardu, Ramona Schmid

Get full text

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK by Kevin Bowrin, Jean-Baptiste Briere, Pierre Levy, Aurélie Millier, Jean Tardu, Mondher Toumi

Get full text

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain by Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere

Get full text

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. by Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere

Get full text